General Information of Drug (ID: DMFKV97)

Drug Name
AC1LG8KT Drug Info
Synonyms BAS 01816608; TCS JNK 5a
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
766949
ChEBI ID
CHEBI:91453
CAS Number
CAS 312917-14-9
TTD Drug ID
DMFKV97

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [4]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [4]
7-azaindole derivative 1 DMQL5B7 N. A. N. A. Patented [4]
7-azaindole derivative 5 DMV3H98 N. A. N. A. Patented [4]
PMID25991433-Compound-P6 DMNDVC9 N. A. N. A. Patented [4]
PMID25991433-Compound-J3 DM17P3F N. A. N. A. Patented [4]
PMID25991433-Compound-P1 DMD8AX6 N. A. N. A. Patented [4]
PMID25991433-Compound-O3 DMVOWS5 N. A. N. A. Patented [4]
PMID25991433-Compound-J2 DMZSOCK N. A. N. A. Patented [4]
7-azaindole derivative 3 DMQ7BV4 N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide DMUFVM6 Discovery agent N.A. Investigative [5]
AS-601245 DMQ95EB Discovery agent N.A. Investigative [6]
Aminopyridine deriv. 2 DM94KQP Discovery agent N.A. Investigative [5]
IN-1166 DMMS6D3 Discovery agent N.A. Investigative [7]
N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide DMY1FMG Discovery agent N.A. Investigative [5]
JNK-IN-8 DMLWYJB Discovery agent N.A. Investigative [8]
N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide DMSAD87 Discovery agent N.A. Investigative [5]
ISIS 18078 DMHZPJ0 Solid tumour/cancer 2A00-2F9Z Investigative [9]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
JNK2 messenger RNA (JNK2 mRNA) TT3IVG2 MK09_HUMAN Inhibitor [2]
Stress-activated protein kinase JNK3 (JNK3) TT056SO MK10_HUMAN Inhibitor [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5996).
2 N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1296-301.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1498).
4 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
5 Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
6 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
7 Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. J Med Chem. 2007 Jun 28;50(13):3143-7.
8 Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
9 US patent application no. 7,425,545, Modulation of C-reactive protein expression.